Business Numinus gets new biosecurity licence to expand psilocybin research CEO Payton Nyquvest says the authorization moves his firm closer to developing medicines at scale to support psychedelic-assisted therapy Nick LabaMarch 14, 2022
Canada Canadian health professionals are limited to clinical trials to access psilocybin. Experts say that’s unethical Health Canada's guidance on how to access illicit substances for medical purposes has been a moving target over the past year Natalia Buendia CalvilloFebruary 16, 2022
Business Numinus uplists to OTCQX Best Market Stock will start trading at market open Thursday under the symbol NUMIF Natalia Buendia CalvilloJanuary 26, 2022
Business Numinus ups revenue 61% thanks to psychedelic-focused therapy programs Expenses were down 71% but the firm still reported a $5.4-million loss Natalia Buendia CalvilloJanuary 21, 2022
Business Numinus submits novel psilocybe formulation for clinical trial If approved, it will mark the firm's first independent clinical trial with a proprietary extract Nick LabaJanuary 14, 2022
Canada What amendments to Canada’s restricted drug program mean for patients and practitioners The new rules will facilitate safer access to substances like psilocybin, but many in need won't qualify, experts say Natalia Buendia CalvilloJanuary 11, 2022
Canada Health Canada to increase legal access to psychedelics for therapy Psychedelics firm Numinus says amendments made to the country's Special Access Programme come into effect in January Natalia Buendia CalvilloDecember 28, 2021
Business Numinus to start trading on TSX The firm will celebrate by ringing the opening bell at the stock exchange on Thursday Kathryn TindaleDecember 15, 2021
Business Numinus ends fiscal year with revenue up 72% to $1.5M, losses of $19M The psychedelics firm has been aggressively expanding lab space while pushing ahead with clinical trials Natalia Buendia CalvilloDecember 10, 2021
Canada Numinus to test natural psilocybin safety in Phase 1 trial Study aims to prove safety of psilocybe mushrooms so Canadian regulators can expand access to psychedelic therapy Jared GnamApril 27, 2021